Nefazodone
Nefazodone is an antidepressant. Its chemical structure is unrelated to selective serotonin reuptake inhibitors, tricyclics, tetracyclics, or monoamine oxidase inhibitors (MAOI). Nefazodone has low affinity for the serotonin (200 nM), norepinephrine (360 nM), and dopamine (360 nM) transporters, and therefore acts as a weak serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI).
For research use only. We do not sell to patients.
Chemical Information
| Name | Nefazodone |
|---|---|
| Iupac Chemical Name | 2-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-5-ethyl-4-(2-phenoxyethyl)-1,2,4-triazol-3-one |
| Synonyms | Nefazodone, Dutonin, Nefadar, Serzone |
| Molecular Formula | C25H32ClN5O2 |
| Molecular Weight | 470.01 |
| Smile | O=C1N(CCCN2CCN(C3=CC=CC(Cl)=C3)CC2)N=C(CC)N1CCOC4=CC=CC=C4 |
| InChiKey | VRBKIVRKKCLPHA-UHFFFAOYSA-N |
| InChi | InChI=1S/C25H32ClN5O2/c1-2-24-27-31(25(32)30(24)18-19-33-23-10-4-3-5-11-23)13-7-12-28-14-16-29(17-15-28)22-9-6-8-21(26)20-22/h3-6,8-11,20H,2,7,12-19H2,1H3 |
| CAS Number | 83366-66-9 |
| Related CAS |
Ordering Information
| Packaging | Price | Availability | Purity | Shipping Time |
|---|---|---|---|---|
| Bulk | Enquiry | Enquiry | Enquiry |
| Formulation | Solid powder |
|---|---|
| Purity | 98% Min. |
| Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
| Solubility | Soluble in DMSO |
| Handling | |
| Shipping Condition | Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs. |
| HS Code |
| Targets | |
|---|---|
| Mechanism | |
| Cell study | |
| Animal study | |
| Clinical study |
1: Karnik NS, Maldonado JR. Antidepressant and statin interactions: a review and case report of simvastatin and nefazodone-induced rhabdomyolysis and transaminitis. Psychosomatics. 2005 Nov-Dec;46(6):565-8. Review. PubMed PMID: 16288136.
2: Masand PS, Gupta S. Long-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine. Ann Clin Psychiatry. 2002 Sep;14(3):175-82. Review. PubMed PMID: 12585567.
3: DeVane CL, Grothe DR, Smith SL. Pharmacology of antidepressants: focus on nefazodone. J Clin Psychiatry. 2002;63 Suppl 1:10-7. Review. PubMed PMID: 11890560.
4: Rotzinger S, Bourin M, Akimoto Y, Coutts RT, Baker GB. Metabolism of some "second"- and "fourth"-generation antidepressants: iprindole, viloxazine, bupropion, mianserin, maprotiline, trazodone, nefazodone, and venlafaxine. Cell Mol Neurobiol. 1999 Aug;19(4):427-42. Review. PubMed PMID: 10379419.
5: Goldberg RJ. Antidepressant use in the elderly. Current status of nefazodone, venlafaxine and moclobemide. Drugs Aging. 1997 Aug;11(2):119-31. Review. PubMed PMID: 9259175.
6: Davis R, Whittington R, Bryson HM. Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression. Drugs. 1997 Apr;53(4):608-36. Review. PubMed PMID: 9098663.
7: Cyr M, Brown CS. Nefazodone: its place among antidepressants. Ann Pharmacother. 1996 Sep;30(9):1006-12. Review. PubMed PMID: 8876863.
8: Ellingrod VL, Perry PJ. Nefazodone: a new antidepressant. Am J Health Syst Pharm. 1995 Dec 15;52(24):2799-812. Review. PubMed PMID: 8748566.
9: Taylor DP, Carter RB, Eison AS, Mullins UL, Smith HL, Torrente JR, Wright RN, Yocca FD. Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug. J Clin Psychiatry. 1995;56 Suppl 6:3-11. Review. PubMed PMID: 7649970.
10: Preskorn SH. Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry. 1995;56 Suppl 6:12-21. Review. PubMed PMID: 7649968.
11: Fontaine R. Novel serotonergic mechanisms and clinical experience with nefazodone. Clin Neuropharmacol. 1993;16 Suppl 3:S45-50. Review. PubMed PMID: 8131154.
12: Eison AS, Eison MS, Torrente JR, Wright RN, Yocca FD. Nefazodone: preclinical pharmacology of a new antidepressant. Psychopharmacol Bull. 1990;26(3):311-5. Review. PubMed PMID: 2274630.
13: Hales RE, Hilty DM, Brunson GH. Cost savings with nefazodone in treating depression. J Clin Psychiatry. 2002;63 Suppl 1:48-51. Review. PubMed PMID: 11890565.
14: Dunner DL, Laird LK, Zajecka J, Bailey L, Sussman N, Seabolt JL. Six-year perspectives on the safety and tolerability of nefazodone. J Clin Psychiatry. 2002;63 Suppl 1:32-41. Review. PubMed PMID: 11890563.
15: Schatzberg AF, Prather MR, Keller MB, Rush AJ, Laird LK, Wright CW. Clinical use of nefazodone in major depression: a 6-year perspective. J Clin Psychiatry. 2002;63 Suppl 1:18-31. Review. PubMed PMID: 11890561.
16: Khouzam HR. The antidepressant nefazodone. A review of its pharmacology, clinical efficacy, adverse effects, dosage, and administration. J Psychosoc Nurs Ment Health Serv. 2000 Aug;38(8):20-5. Review. PubMed PMID: 10959472.
17: Horst WD, Preskorn SH. Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion. J Affect Disord. 1998 Dec;51(3):237-54. Review. PubMed PMID: 10333980.
18: Owen JR, Nemeroff CB. New antidepressants and the cytochrome P450 system: focus on venlafaxine, nefazodone, and mirtazapine. Depress Anxiety. 1998;7 Suppl 1:24-32. Review. PubMed PMID: 9597349.
19: Greene DS, Barbhaiya RH. Clinical pharmacokinetics of nefazodone. Clin Pharmacokinet. 1997 Oct;33(4):260-75. Review. PubMed PMID: 9342502.
20: Augustin BG, Cold JA, Jann MW. Venlafaxine and nefazodone, two pharmacologically distinct antidepressants. Pharmacotherapy. 1997 May-Jun;17(3):511-30. Review. PubMed PMID: 9165554.
Chemical Structure
